US free shipping over $150 · Exact worldwide rate at checkout · Crypto-only checkout guide — Shop now
T
Titan PeptideResearch-grade nasal sprays

Tirzepatide · cycle length · research use only

How long is a tirzepatide cycle? Why a dual agonist has its own answer — and it isn't 'weeks on, weeks off.'

Search 'tirzepatide cycle length' and you'll get the on/off framing people apply to BPC-157 or a growth-hormone secretagogue — run it for X weeks, then take a break. For a GIP/GLP-1 dual agonist that framing is a category error, and tirzepatide is the one compound in this whole class that has a purpose-built trial answering the underlying question directly. SURMOUNT-4 (Aronne et al., JAMA 2024) ran a 36-week open-label lead-in, then randomised participants either to continue tirzepatide or switch to placebo — a deliberate withdrawal experiment. The continuation group lost a further ~6.7% of body weight over the next 52 weeks; the group taken off the drug regained ~14%. That is tirzepatide's own data on what stopping does, not a figure borrowed from another peptide. The pivotal efficacy trials point the same way: SURMOUNT-1 (Jastreboff et al., NEJM 2022) dosed continuously for 72 weeks with the response still building, and diabetes/obesity programmes have followed patients to 104 weeks of continuous therapy. There is no on/off 'cycle' arm anywhere in the tirzepatide literature. This page lays out what tirzepatide's own trials establish, why the cycling concept doesn't transfer, and the one genuine schedule that does exist: the multi-month titration ramp. It is a research reference summarising published trial data and pharmacology — not a human-use schedule, not dosing or medical advice.

Retatrutide — $199.99Tirzepatide dosage & titration

'Cycling' is a bodybuilding-peptide concept — it doesn't transfer to an incretin agonist

The on/off cycling idea comes from repair and growth-hormone peptides, where the rationale is either caution (no long-term human data) or a genuine kinetic driver (pulsing a GH secretagogue to preserve receptor responsiveness). A GIP/GLP-1 dual agonist has neither as a reason to schedule breaks. In the metabolic-agonist literature tirzepatide is studied as continuous therapy, and importing a 'weeks on, weeks off' block from a different peptide class misreads what the compound is and how it was actually trialled.

How repair-peptide cycling differs →

Tirzepatide has its OWN withdrawal trial — SURMOUNT-4

Most drugs in this class only have discontinuation data inferred from a sibling compound. Tirzepatide doesn't need to borrow: SURMOUNT-4 (Aronne et al., JAMA 2024) was purpose-built to test stopping. After a 36-week lead-in, participants were randomised to continue tirzepatide or switch to placebo. Over the following 52 weeks the placebo (stopped) group regained ~14% of body weight, while continuation added a further ~6.7% loss — a ~21 percentage-point gap that opened up purely from stopping. That is the single most direct answer to 'do you cycle off tirzepatide' available for any compound in the class.

Adverse-event profile →

The pivotal trials ran 72 weeks continuously — with the curve still moving

SURMOUNT-1 (Jastreboff et al., NEJM 2022) dosed tirzepatide continuously for 72 weeks and reported up to ~21% mean body-weight reduction at the top dose, with the response still building near study end rather than plateauing into a planned break. Longer diabetes and obesity programmes have carried patients to 104 weeks of continuous therapy. Reading a fixed trial duration as a 'recommended cycle length' repeats the mistake the preclinical peptide pages make: a study endpoint is not a schedule, and here the endpoints were continuous, not cyclical.

The 72-week response curve →

Why trialists frame it as chronic therapy, not a cycle

The SURMOUNT-4 result is why the field describes obesity as a chronic condition needing ongoing treatment: the effect is maintained while the drug is on board and largely reverses when it comes off. That is the published position on duration for the dual-agonist class — continuous treatment to hold the effect, not a fixed run followed by a planned rest. Any page presenting tirzepatide as a compound you 'cycle off' is applying a framework its own randomised withdrawal trial points directly away from.

Retatrutide vs tirzepatide →

The one genuine schedule: the titration ramp

The closest thing tirzepatide has to a 'schedule' is dose escalation, not a cycle. The label steps the weekly dose up gradually — 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg — at multi-week intervals, a ramp designed to limit the gastrointestinal side effects that cluster during escalation. That is a real, published structure worth understanding, and it's an ascending ladder rather than an on/off loop. The dosage page walks through the titration steps and the reconstitution math that sets each week's draw volume.

Titration ladder & recon math →

Research-use framing (and why Titan lists retatrutide instead)

Everything here summarises published clinical-trial designs and pharmacology reproduced as a research reference for laboratory and in-vitro modelling — not instructions for human use, and not a claim of efficacy or an optimal schedule in people. Titan does not stock tirzepatide; the in-house-tested metabolic reagent we carry is retatrutide, a GLP-1/GIP/glucagon triple agonist studied in the same continuous-therapy way. Nothing on this page is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

Tirzepatide 'cycle length', separated into evidence and assumption.

A plain-terms split between what tirzepatide's own trials establish about duration and the on/off 'cycle' assumptions imported from unrelated peptide classes. The trial figures are continuous-treatment and randomised-withdrawal data from tirzepatide's own programme; the 'cycle' figures have no controlled-trial basis for this drug class. Reproduced as a research reference, not a human-use schedule.

Validated 'cycle length'
None. No trial of tirzepatide tested an on/off cycle. It was studied as continuous therapy, and its withdrawal trial studied stopping outright — not cycling.
Dedicated withdrawal trial
SURMOUNT-4 (Aronne et al., JAMA 2024): 36-week lead-in, then continue vs switch-to-placebo. Stopping → ~14% regain over 52 weeks; continuing → ~6.7% further loss.
Pivotal trial duration
SURMOUNT-1 (Jastreboff et al., NEJM 2022): 72 weeks continuous; up to ~21% mean weight loss at the top dose, response still building at study end.
Longest continuous follow-up
Diabetes/obesity programmes have dosed continuously to ~104 weeks — no on/off cycle arm anywhere in the literature.
Trialists' stated model
Chronic condition requiring long-term therapy — continuous treatment to maintain effect, explicitly not an on/off cycle.
The real schedule that exists
Dose titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, stepped up over months to limit GI effects during ramp-up — an ascending ladder, not a cycle.
Reason peptides get cycled (for contrast)
Repair peptides: caution (no long-term data). GH secretagogues: receptor resensitisation. Tirzepatide has neither driver.
Titan catalog status
Tirzepatide not stocked. Titan's in-house-tested metabolic reagent is retatrutide ($199.99), a triple agonist trialled the same continuous way.

Questions researchers ask

Before you order.

How long should a tirzepatide cycle be?
The premise doesn't fit the drug. Tirzepatide is a GIP/GLP-1 dual agonist, and its trials did not use on/off cycles — SURMOUNT-1 (NEJM 2022) dosed continuously for 72 weeks and its dedicated withdrawal trial, SURMOUNT-4 (JAMA 2024), tested stopping outright rather than cycling. There is no research-validated 'cycle length' because the class isn't cycled; it's studied as continuous therapy. Any specific 'X weeks on, then off' figure you see for tirzepatide is imported from repair or growth-hormone peptides and has no controlled-trial basis for this compound. This page is a research reference summarising that evidence, not a human-use schedule.
Do you have to cycle off tirzepatide?
Tirzepatide is the one compound in this class with a purpose-built trial on exactly that question, and it points the other way. SURMOUNT-4 (Aronne et al., JAMA 2024) randomised participants after a 36-week lead-in to continue the drug or switch to placebo: the group taken off regained about 14% of body weight over the next year, while those who continued lost a further ~6.7%. The trialists concluded obesity behaves as a chronic condition requiring long-term therapy. So in the research context these agents are framed as continuous rather than cycled. Nothing here is medical advice; it summarises what the trial reported.
Why is tirzepatide not cycled like BPC-157 or CJC-1295/ipamorelin?
Because the reasons those peptides are cycled don't apply. BPC-157's cycling convention rests on the absence of long-term human safety data (a caution argument), and growth-hormone secretagogues like CJC-1295/ipamorelin are pulsed to preserve pituitary receptor responsiveness (a mechanism-based driver). A GIP/GLP-1 dual agonist has neither — no demonstrated desensitisation requiring breaks, and it was trialled as continuous therapy with a randomised withdrawal arm rather than an on/off cycle. Same word, 'cycle', but a completely different underlying logic.
Is there any real 'schedule' for tirzepatide?
Yes — but it's titration, not a cycle. The label escalates the weekly dose gradually (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) at multi-week intervals to reach the higher targets, a ramp designed to limit the gastrointestinal side effects that cluster during dose escalation. That is an ascending ladder with a defined structure, not an on-then-off loop. The dosage page covers the titration steps and the reconstitution math that determines each week's draw volume.
Does Titan sell tirzepatide?
No. Titan Peptide Lab does not stock tirzepatide. The in-house-tested metabolic research reagent we carry is retatrutide ($199.99), a GLP-1/GIP/glucagon triple agonist studied in the same continuous-therapy manner. Everything on this page is a research reference summarising published trial data on tirzepatide — supplied for context, not as dosing or medical advice, and not for human or animal consumption.

Related reading

Before you check out.